DE69803670D1 - Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung - Google Patents

Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung

Info

Publication number
DE69803670D1
DE69803670D1 DE69803670T DE69803670T DE69803670D1 DE 69803670 D1 DE69803670 D1 DE 69803670D1 DE 69803670 T DE69803670 T DE 69803670T DE 69803670 T DE69803670 T DE 69803670T DE 69803670 D1 DE69803670 D1 DE 69803670D1
Authority
DE
Germany
Prior art keywords
tiagabine
hours
active substance
substance administration
controlled active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69803670T
Other languages
English (en)
Other versions
DE69803670T2 (de
Inventor
Joseph Clancy
Michelle Caulfield
Iain Cumming
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Elan Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26320083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69803670(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from IE19970588A external-priority patent/IE970588A1/en
Application filed by Elan Corp PLC filed Critical Elan Corp PLC
Application granted granted Critical
Publication of DE69803670D1 publication Critical patent/DE69803670D1/de
Publication of DE69803670T2 publication Critical patent/DE69803670T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
DE69803670T 1997-08-01 1998-07-30 Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung Expired - Lifetime DE69803670T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5443297P 1997-08-01 1997-08-01
IE19970588A IE970588A1 (en) 1997-08-01 1997-08-08 Controlled release pharmaceutical compositions containing tiagabine
PCT/IE1998/000067 WO1999006045A1 (en) 1997-08-01 1998-07-30 Controlled release pharmaceutical compositions containing tiagabine

Publications (2)

Publication Number Publication Date
DE69803670D1 true DE69803670D1 (de) 2002-03-14
DE69803670T2 DE69803670T2 (de) 2002-11-21

Family

ID=26320083

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69803670T Expired - Lifetime DE69803670T2 (de) 1997-08-01 1998-07-30 Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung

Country Status (10)

Country Link
EP (1) EP0991409B1 (de)
JP (1) JP2001511450A (de)
AT (1) ATE212550T1 (de)
AU (1) AU8643698A (de)
CA (1) CA2299464C (de)
DE (1) DE69803670T2 (de)
DK (1) DK0991409T3 (de)
ES (1) ES2172179T3 (de)
PT (1) PT991409E (de)
WO (1) WO1999006045A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002325404B2 (en) * 1998-01-22 2006-02-02 Abbott Laboratories Extended Release Tiagabine Formulations with Reduced Side-effects
ZA99407B (en) * 1998-01-22 1999-07-20 Abbott Lab Extended release tiagabine formulations with reduced side-effects.
EP1205190B1 (de) * 1999-08-04 2006-05-03 Astellas Pharma Inc. Stabile medizinische zusammensetzungen zur oralen verabreichung unter verwendung von eisenoxiden
KR100510270B1 (ko) * 2002-11-29 2005-08-26 센츄론(주) 펠렛타이저를 이용한 서방성 제제의 제조방법
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
US20040224017A1 (en) * 2003-03-14 2004-11-11 Nirmal Mulye Process for preparing sustained release tablets
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
JP2016520653A (ja) 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
ZA953078B (en) * 1994-04-28 1996-01-05 Alza Corp Effective therapy for epilepsies
US5750140A (en) * 1994-05-20 1998-05-12 Novo Nordisk A/S Transdermal delivery of tiagabine
MX9708394A (es) * 1995-05-05 1998-02-28 Novo Nordisk As Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
DE19525598C2 (de) * 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
WO1997043902A1 (en) * 1996-05-24 1997-11-27 Smithkline Beecham Corporation Use of gaba uptake inhibitors as anti-tussive agents
UA52661C2 (uk) * 1996-06-14 2003-01-15 Ново Нордіск А/С Безводна кристалічна форма гідрохлориду r(-)-n-(4,4-ди(3-метилтієн-2-іл)бут-3-еніл) ніпекотинової кислоти
US5914333A (en) * 1996-07-31 1999-06-22 Novo Nordisk A/S Treatment of psychotic disorders

Also Published As

Publication number Publication date
CA2299464A1 (en) 1999-02-11
CA2299464C (en) 2009-02-17
ES2172179T3 (es) 2002-09-16
PT991409E (pt) 2002-06-28
DE69803670T2 (de) 2002-11-21
ATE212550T1 (de) 2002-02-15
AU8643698A (en) 1999-02-22
WO1999006045A1 (en) 1999-02-11
EP0991409B1 (de) 2002-01-30
JP2001511450A (ja) 2001-08-14
DK0991409T3 (da) 2002-03-25
EP0991409A1 (de) 2000-04-12

Similar Documents

Publication Publication Date Title
BR0014383A (pt) Composições de liberação controlada compreendendo nimesulida
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
NZ508526A (en) Opioid formulations for treating pain
NO944565L (no) Preparat med regulert frigjörelse som inneholder et morfinsalt
YU49495B (sh) Formulacije oksikodona sa kontrolisanim otpuštanjem i njihova upotreba
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
DE69433818D1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
AU681452B2 (en) Pernasal composition and pernasal preparation containing thesame
BR0108435A (pt) Formulação e uso de entecavir de baixa dose
ATE240344T1 (de) Nor-pregnane zur induzierung hypothalamischer effekte
BR0013719A (pt) Dosagem oral de liberaçâo controlada, apropriada para administração oral
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
DE69803670D1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung
DE69307807D1 (de) Naproxen-Tabletten mit gesteuerter Wirkstoffabgabe
ATE256134T1 (de) Sulfatierte phosphatidylinositole, ihre herstellung und verwendung
WO2002056867A3 (en) Extended release pharmaceutical compositions containing beta-lactam antibiotics
JO2296B1 (en) Substituted pyrolates
DE69808287T2 (de) Pharmazeutische zusammensetzungen von cinchonin dihydrochlorid
ES8303915A1 (es) "procedimiento para la preparacion de comprimidos a base del antibiotico fosfomicina".

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: CEPHALON, INC., WEST CHESTER, PA., US